TrialDiabetes, obesity & metabolism2019

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.

Wenying Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.